CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma

Chemoradiation is a common therapeutic regimen for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). However, not all patients benefit from chemotherapy, especially patients with low-risk characteristics. We aim to develop and validate a prognostic and predictive r...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Bolin, Yang, Kailin, Viswanathan, Vidya Sankar, Wang, Xiangxue, Lee, Jonathan, Stock, Sarah, Fu, Pingfu, Lu, Cheng, Koyfman, Shlomo, Lewis, James S., Madabhushi, Anant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238543/
https://www.ncbi.nlm.nih.gov/pubmed/37268691
http://dx.doi.org/10.1038/s41698-023-00404-w
_version_ 1785053317521473536
author Song, Bolin
Yang, Kailin
Viswanathan, Vidya Sankar
Wang, Xiangxue
Lee, Jonathan
Stock, Sarah
Fu, Pingfu
Lu, Cheng
Koyfman, Shlomo
Lewis, James S.
Madabhushi, Anant
author_facet Song, Bolin
Yang, Kailin
Viswanathan, Vidya Sankar
Wang, Xiangxue
Lee, Jonathan
Stock, Sarah
Fu, Pingfu
Lu, Cheng
Koyfman, Shlomo
Lewis, James S.
Madabhushi, Anant
author_sort Song, Bolin
collection PubMed
description Chemoradiation is a common therapeutic regimen for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). However, not all patients benefit from chemotherapy, especially patients with low-risk characteristics. We aim to develop and validate a prognostic and predictive radiomic image signature (pRiS) to inform survival and chemotherapy benefit using computed tomography (CT) scans from 491 stage I and II HPV-associated OPSCC, which were divided into three cohorts D(1)–D(3). The prognostic performance of pRiS was evaluated on two test sets (D(2), n = 162; D(3), n = 269) using concordance index. Patients from D(2) and D(3) who received either radiotherapy alone or chemoradiation were used to validate pRiS as predictive of added benefit of chemotherapy. Seven features were selected to construct pRiS, which was found to be prognostic of overall survival (OS) on univariate analysis in D(2) (hazard ratio [HR] = 2.14, 95% confidence interval [CI], 1.1–4.16, p = 0.02) and D(3) (HR = 2.74, 95% CI, 1.34–5.62, p = 0.006). Chemotherapy was associated with improved OS for high-pRiS patients in D(2) (radiation vs chemoradiation, HR = 4.47, 95% CI, 1.73–11.6, p = 0.002) and D(3) (radiation vs chemoradiation, HR = 2.99, 95% CI, 1.04–8.63, p = 0.04). In contrast, chemotherapy did not improve OS for low-pRiS patients, which indicates these patients did not derive additional benefit from chemotherapy and could be considered for treatment de-escalation. The proposed radiomic signature was prognostic of patient survival and informed benefit from chemotherapy for stage I and II HPV-associated OPSCC patients.
format Online
Article
Text
id pubmed-10238543
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102385432023-06-04 CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma Song, Bolin Yang, Kailin Viswanathan, Vidya Sankar Wang, Xiangxue Lee, Jonathan Stock, Sarah Fu, Pingfu Lu, Cheng Koyfman, Shlomo Lewis, James S. Madabhushi, Anant NPJ Precis Oncol Article Chemoradiation is a common therapeutic regimen for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). However, not all patients benefit from chemotherapy, especially patients with low-risk characteristics. We aim to develop and validate a prognostic and predictive radiomic image signature (pRiS) to inform survival and chemotherapy benefit using computed tomography (CT) scans from 491 stage I and II HPV-associated OPSCC, which were divided into three cohorts D(1)–D(3). The prognostic performance of pRiS was evaluated on two test sets (D(2), n = 162; D(3), n = 269) using concordance index. Patients from D(2) and D(3) who received either radiotherapy alone or chemoradiation were used to validate pRiS as predictive of added benefit of chemotherapy. Seven features were selected to construct pRiS, which was found to be prognostic of overall survival (OS) on univariate analysis in D(2) (hazard ratio [HR] = 2.14, 95% confidence interval [CI], 1.1–4.16, p = 0.02) and D(3) (HR = 2.74, 95% CI, 1.34–5.62, p = 0.006). Chemotherapy was associated with improved OS for high-pRiS patients in D(2) (radiation vs chemoradiation, HR = 4.47, 95% CI, 1.73–11.6, p = 0.002) and D(3) (radiation vs chemoradiation, HR = 2.99, 95% CI, 1.04–8.63, p = 0.04). In contrast, chemotherapy did not improve OS for low-pRiS patients, which indicates these patients did not derive additional benefit from chemotherapy and could be considered for treatment de-escalation. The proposed radiomic signature was prognostic of patient survival and informed benefit from chemotherapy for stage I and II HPV-associated OPSCC patients. Nature Publishing Group UK 2023-06-02 /pmc/articles/PMC10238543/ /pubmed/37268691 http://dx.doi.org/10.1038/s41698-023-00404-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Song, Bolin
Yang, Kailin
Viswanathan, Vidya Sankar
Wang, Xiangxue
Lee, Jonathan
Stock, Sarah
Fu, Pingfu
Lu, Cheng
Koyfman, Shlomo
Lewis, James S.
Madabhushi, Anant
CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma
title CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma
title_full CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma
title_fullStr CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma
title_full_unstemmed CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma
title_short CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma
title_sort ct radiomic signature predicts survival and chemotherapy benefit in stage i and ii hpv-associated oropharyngeal carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238543/
https://www.ncbi.nlm.nih.gov/pubmed/37268691
http://dx.doi.org/10.1038/s41698-023-00404-w
work_keys_str_mv AT songbolin ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma
AT yangkailin ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma
AT viswanathanvidyasankar ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma
AT wangxiangxue ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma
AT leejonathan ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma
AT stocksarah ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma
AT fupingfu ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma
AT lucheng ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma
AT koyfmanshlomo ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma
AT lewisjamess ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma
AT madabhushianant ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma